Newtyn Management’s iTeos Therapeutics ITOS Stock Holding History

Newtyn Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-567,416	Closed	-$5.66M	–	36
2025 Q2	$5.66M	Buy	+567,416	New	+$4.57M	0.86%	26

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Newtyn Management's ITOS Position: Q3 2025 in Review

Newtyn Management sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 567,416 shares — an estimated $5.66M sold.

Newtyn Management first reported a position in ITOS in Q2 2025 and held it in 1 quarter. The position peaked at $5.66M in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Newtyn Management reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Newtyn Management sold 567,416 iTeos Therapeutics shares in Q3 2025, an estimated $5.66M.
Newtyn Management first reported a position in iTeos Therapeutics in Q2 2025 and held it in 1 quarter.
Newtyn Management's iTeos Therapeutics position peaked at $5.66M in Q2 2025.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Newtyn Management's 13F filing for Q3 2025, filed 14 Nov 2025.